4 articles
RadNet's adjusted EBITDA rose 36.3% year-over-year in Q1 2026, well ahead of its 22.1% revenue growth, driven by AI scheduling and diagnostic tools across its U.S. network. Advanced imaging volumes surged, with PET/CT up 35.2% and MRI same-center volume up 10.1%. The margin expansion offers a concrete financial reference point for hospital systems worldwide evaluating AI investment in radiology.
NVIDIA's BioNeMo platform has secured partnerships with pharmaceutical giants Eli Lilly and Thermo Fisher Scientific, alongside AI biotech firms Terray Therapeutics and Apheris. The platform provides AI infrastructure for computational drug discovery, targeting an industry where R&D costs average billions per approved drug across global markets.
Google requires users to click 'Show More' to see full safety warnings on AI-generated medical advice, MIT Technology Review found. The practice comes as antimicrobial-resistant infections kill over 4 million people yearly worldwide, raising stakes for algorithmic health guidance.
Intuitive Surgical secured regulatory approvals for its da Vinci 5 robotic system in Europe and Japan, unlocking markets worth $2.3 billion in annual surgical robotics spending. The company beat Q4 earnings forecasts while installing 415 systems globally, a 22% increase year-over-year. Force feedback and AI-powered features distinguish the new platform as competition intensifies across international markets.